Skip To Content
Click for DHHS Home Page
Click for the SAMHSA Home Page
Click for the OAS Drug Abuse Statistics Home Page
Click for What's New
Click for Recent Reports and HighlightsClick for Information by Topic Click for OAS Data Systems and more Pubs Click for Data on Specific Drugs of Use Click for Short Reports and Facts Click for Frequently Asked Questions Click for Publications Click to send OAS Comments, Questions and Requests Click for OAS Home Page Click for Substance Abuse and Mental Health Services Administration Home Page Click to Search Our Site

Services Research Outcomes Study (SROS)

Previous Page TOC Next Page


  1. HISTORY OF THE SROS SAMPLE

HISTORY OF THE SROS SAMPLE

Two data collections frame the Services Research Outcomes Study (SROS): the Uniform Facility Data Set/National Drug and Alcoholism Treatment Unit Survey (UFDS/NDATUS) represents the first data collection effort, and the Drug Services Research Survey (DSRS) the second.

A detailed description of the DSRS, subsequent SROS facility universe, the facility sample, and client sample is presented in Tables 2-1 and 2-2. The April 1990, 10,649 facilities constituted the known substance abuse treatment facilities in the continental United States that served as the sampling universe. DSRS first sampled 1,803 facilities for its Phase I survey of facilities; 1,442 proved eligible (as active treatment facilities in the continental United States), and 1,183 of the eligible facilities responded, comprising 138 hospital inpatient facilities, 185 residential, 80 outpatient methadone detoxification/maintenance, 372 outpatient drug-free, 91 alcohol-only, and 317 whose facility type was unknown.

Since DSRS’ focus was on clients discharged from drug treatment facilities, the alcohol-only and treatment-type unknown facilities were excluded from the Phase II facility sample frame.


Table 2-1. Development of the SROS Client Sample




Principal Facility Type


Total


Hospital Inpatient

Residential

Outpatient Methadone

Outpatient Drug-Free

Alcohol Treatment Only

Treatment Unknown

Other

Known Facility Universe - April 19901

10,649


693

1,172

467

2,953

1,291

4,073


DSRS Phase I—1990










Stratified Facility Sample

1,803


179

216

103

526

187

592


Screened for Eligibility

1,760


178

213

102

520

183

561


Eligible Facilities

1,442


166

202

93

449

114

418


cumulative response rate

100%


100%

100%

100%

100%

100%

100%


Facility Respondents

1,183


138

185

80

372

91

317


cumulative response rate

82%


83%

92%

86%

83%

80%

76%


DSRS Phase II—19912










Subsample of Facilities

146


40

34

38

34

NONE SAMPLED

Cooperating Facilities for Abstraction

120


29

32

31

28

cumulative response rate

67%


60%

86%

70%

68%

Records Abstracted

2,222


571

615

549

487




Facility Type Reported on the Abstract3

2,182


421

496

292

500

255

138

80

SROS—1995










Recapture of Cooperating Facilities

99


22

27

26

24

NONE SAMPLED

cumulative response rate

56%


46%

73%

59%

58%

Records Abstracted4

3,047


758

779

735

775

Eligible After Screening5

3,033


757

773

732

771

Deceased

277


107

43

85

42

Eligible for Interview

2,756


650

730

647

729

Interviewed

1,799


441

464

423

471

cumulative response rate

38%


33%

48%

41%

39%

Respondent-Reported Facility Type3

1,799


700

326

217

556




1 Source: Table 1, Drug Services Research Survey (DSRS) Final Report: Phase I, February 22, 1993.

2 Source: Tables 2 and 4, Drug Services Research Survey (DSRS) Final Report: Phase II, February 12, 1992.


3 Facilities with more than one type of unit were classified according to their principal facility type (the type reporting the largest number of cases). Records for abstraction at times were drawn from more than one type within a multitype facility; and interviewed clients at times identified the treatment episode as occurring within a facility type other than the principal one.

4 In order to meet precision requirements for the interview data, the probability sample of records abstracted was increased to 3,047.

5 Of the 3,047 abstracted records, 12 case records were determined not to cover the SROS treatment episode, 1 case was not actually admitted to treatment, and 1 record was a duplicate, for a total of 14 ineligible records.

Table 2-2. Detailed Disposition of 3,047 Abstracted Client Records




Facility Type


Total


Hospital

Inpatient

Residential

Outpatient

Detox/Main-

tenance

Outpatient

Drug-Free

Client Records Abstracted

3,047


758

779

735

775


100%


100%

100%

100%

100%

Interview Completed

1,799


441

464

423

471


59%


58%

60%

58%

61%

Deceased

277


107

43

85

42


9%


14%

6%

12%

5%

Not Located

558


109

166

150

135


18%


14%

21%

20%

17%

Other1

413


101

106

77

127


14%


13%

14%

10%

16%








SROS Response Rate2

68%


72%

66%

69%

67%

1 "Other" includes respondents who were ineligible after screening of the abstracts (see Table 2-1 note 5), refused to perform an interview, agreed to be interviewed but broke all appointments, were in locations that were not accessible for interviewing in person or by telephone, or were too ill or disabled to conduct an interview.

2 Interviewees and deceased are considered as completed cases in calculating the SROS response rate.

DSRS Phase II randomly selected 146 facilities from the DSRS Phase I facility respondents and abstracted 2,222 client records from 120 facilities in the four strata of: hospital inpatient, residential, outpatient detoxification/maintenance, and outpatient drug-free treatment.

The DSRS sample of 120 facilities was the base from which the SROS sample was contacted. When SROS staff approached the 120 facilities to seek enrollment in the SROS protocol of record reabstraction, sample supplementation, and client interviews, a dozen facilities were no longer operational and a larger number had changed ownership or leadership in the interim. SROS gained the cooperation of 99 of the 120 DSRS facilities. SROS supplemented the DSRS client sample target from these 99, increasing the sample from 2,222 to 3,047 clients who had been discharged in the 12 months ending August 31, 1990.

Of the 3,047 clients whose records were abstracted during 1994, 2,489 clients (82 percent) in the sample were located during the nine month 1995–1996 field period. A detailed description of field data collection is presented in the Appendix A. Nine percent (277 clients) of the sample of 3,047 had died between discharge from drug treatment and the SROS field period. Twelve percent (351 clients) refused or were unavailable for interview before the end of the interview period, less than one percent (14 clients) proved ineligible for the study, and 1,799 were successfully interviewed, comprising 59 percent of the total sample, 65 percent of those alive and eligible for the study, and 82 percent of those alive and located during the field period. The remaining 558 clients (18 percent) were not located before time and resources for fieldwork expired.

There is a difference between simple response rates and cumulative response rates. The overall completion rate was 65 percent when those who died before the field period are excluded. The completion rate for subgroups of the sample are: 63 percent for males, 70 percent for females, 65 percent for white non-Hispanics, 66 percent for black non-Hispanics, and 54 percent for Hispanics.

When those who died before the field period are counted as completions, the overall completion rate was 68 percent. The completion rate for subgroups of the sample are: 67 percent for males, 72 percent for females, 68 percent for white non-Hispanics, 69 percent for black non-Hispanics, and 59 percent for Hispanics.

When SROS is viewed as part of a longitudinal study, following DSRS Phase I, DSRS Phase II, the recapture of DSRS facilities for SROS, and the completion of cases for SROS, the cumulative response rate would be the product of each of the four individual response rates. [NOTE: The computation is (.82)(.82)(.83)(.68) = 38 percent as shown on Table 2-1.]

Whenever respondents to a study are not 100 percent of those eligible for inclusion, the respondents’ representativeness [The question centers on whether the respondents who were not included were lost to followup for essentially random and unconnected reasons. If so, the loss of those data would not introduce any distortions or biases into the data, but would only result in some loss in precision due to a smaller sample size than might otherwise have been achieved .] is always an important issue. The following section analyzes the extent of bias introduced by nonresponse, comparing the clients interviewed with those not interviewed.

Previous Page Page Top TOC Next Page
This is the page footer.

This page was last updated on June 03, 2008.

SAMHSA, an agency in the Department of Health and Human Services, is the Federal Government's lead agency for improving the quality and availability of substance abuse prevention, addiction treatment, and mental health services in the United States.

Yellow Line

Site Map | Contact Us | Accessibility Privacy PolicyFreedom of Information ActDisclaimer  |  Department of Health and Human ServicesSAMHSAWhite HouseUSA.gov

* Adobe™ PDF and MS Office™ formatted files require software viewer programs to properly read them. Click here to download these FREE programs now

What's New

Highlights Topics Data Drugs Pubs Short Reports Treatment Help Mail OAS